Published in Vaccine Weekly, August 27th, 2003
"The initiation of clinical trials with our technology marks a very exciting milestone not just for those working on HIV vaccines but for the entire vaccine field," said Peter Young, president & CEO of AlphaVax. "This kind of novel technology has the potential to reshape the vaccine marketplace, and it is very gratifying to demonstrate that we can translate this state-of-the-art science into products whose promise can be tested and advanced in the clinic."
The ArV vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly